Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Semaglutide may be prescribed for different reasons and some forms may be more suitable for you than others: Ozempic. Ozempic is approved by the FDA (U.S. Food and Drug Administration) for type 2 ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

The Food and Drug Administration (“FDA”) has removed semaglutide from its drug shortage list after the agency determined the current supply of ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Semaglutide is the active ingredient in the ... Ozempic is a weekly injection approved by the FDA (U.S. Food and Drug Administration) to treat type 2 diabetes. It’s sometimes prescribed off ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...